Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Prebet T"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-15 z 15
    Tytuł:
    Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial.
    Autorzy:
    Cortes JE; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA. .; Georgia Cancer Center, Augusta University, 1410 Laney Walker Rd, CN2222, Augusta, GA, 30912, USA. .
    Lin TL; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
    Asubonteng K; Department of Biostatistics, Jazz Pharmaceuticals, Philadelphia, PA, USA.
    Faderl S; Department of Clinical Development, Jazz Pharmaceuticals, Palo Alto, CA, USA.
    Lancet JE; Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
    Prebet T; Department of Hematology, Yale School of Medicine, New Haven, CT, USA.
    Pokaż więcej
    Źródło:
    Journal of hematology & oncology [J Hematol Oncol] 2022 Oct 26; Vol. 15 (1), pp. 155. Date of Electronic Publication: 2022 Oct 26.
    Typ publikacji:
    Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Leukemia, Myeloid, Acute*
    Neoplasms, Second Primary*/drug therapy
    Aged ; Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cytarabine/adverse effects ; Daunorubicin/adverse effects
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia.
    Autorzy:
    Prebet T; Hematology, Yale University, New Haven, Connecticut, United States.
    Goldberg AD; Memorial Sloan Kettering Cancer Center, New York, New York, United States.
    Jurcic JG; Columbia University Irving Medical Center, New York, New York, United States.
    Khaled S; City of Hope, Duarte, California, United States.
    Dail M; Genentech, Inc, South San Francisco, California, United States.
    Feng Y; Genentech, Inc, South San Francisco, California, United States.
    Green C; Genentech, Inc, South San Francisco, California, United States.
    Li C; Genentech, Inc, South San Francisco, California, United States.
    Ma C; Genentech, Inc, South San Francisco, California, United States.
    Medeiros BC; Genentech, Inc, South San Francisco, California, United States.
    Yan M; Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada.
    Grunwald MR; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, United States.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2022 Sep; Vol. 63 (9), pp. 2180-2188. Date of Electronic Publication: 2022 May 01.
    Typ publikacji:
    Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Azacitidine*/analogs & derivatives
    Azacitidine*/therapeutic use
    Leukemia, Myeloid, Acute*/diagnosis
    Leukemia, Myeloid, Acute*/drug therapy
    Aged ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Humans
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.
    Autorzy:
    Bewersdorf JP; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USA.
    Derkach A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Gowda L; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USA.
    Menghrajani K; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY, USA.
    DeWolf S; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
    Ruiz JD; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Ponce DM; Weill Cornell Medical College, New York, NY, USA.; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Shaffer BC; Weill Cornell Medical College, New York, NY, USA.; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Tamari R; Weill Cornell Medical College, New York, NY, USA.; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Young JW; Weill Cornell Medical College, New York, NY, USA.; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; The Rockefeller University, New York, NY, USA.
    Jakubowski AA; Weill Cornell Medical College, New York, NY, USA.; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Gyurkocza B; Weill Cornell Medical College, New York, NY, USA.; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Chan A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Xiao W; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Glass J; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY, USA.
    King AC; Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Cai SF; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY, USA.
    Daniyan A; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY, USA.
    Famulare C; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
    Cuello BM; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
    Podoltsev NA; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USA.
    Roshal M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Giralt S; Weill Cornell Medical College, New York, NY, USA.; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Perales MA; Weill Cornell Medical College, New York, NY, USA.; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Seropian S; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USA.
    Cho C; Weill Cornell Medical College, New York, NY, USA.; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USA.
    Prebet T; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale University, New Haven, CT, USA.
    Stein EM; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY, USA.
    Tallman MS; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY, USA.
    Goldberg AD; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY, USA.
    Stahl M; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Weill Cornell Medical College, New York, NY, USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2021 Dec; Vol. 62 (14), pp. 3394-3401. Date of Electronic Publication: 2021 Sep 03.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Hematopoietic Stem Cell Transplantation*/adverse effects
    Hematopoietic Stem Cell Transplantation*/methods
    Leukemia, Myeloid, Acute*/diagnosis
    Leukemia, Myeloid, Acute*/therapy
    Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Humans ; Retrospective Studies ; Sulfonamides
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis.
    Autorzy:
    Zhao J; Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, USA.
    Bewersdorf JP; Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
    Jaszczur S; Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, USA.
    Kowalski A; Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, USA.
    Perreault S; Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, USA.
    Schiffer M; Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, USA.
    Gore S; Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT, USA.
    Podoltsev N; Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT, USA.
    Prebet T; Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT, USA.
    Shallis R; Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT, USA.
    Zeidan AM; Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT, USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2021 May; Vol. 62 (5), pp. 1195-1202. Date of Electronic Publication: 2020 Dec 16.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Leukemia, Myeloid, Acute*/drug therapy
    Leukostasis*/diagnosis
    Leukostasis*/etiology
    Leukostasis*/therapy
    Cyclophosphamide/adverse effects ; Cytoreduction Surgical Procedures ; Humans ; Leukapheresis ; Leukocytosis
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.
    Autorzy:
    Stahl M; a Department of Internal Medicine, Section of Hematology, Yale University School of Medicine , New Haven , CT, USA.
    DeVeaux M; b Department of Biostatistics, Yale School of Public Health , New Haven , CT, USA.
    Montesinos P; c Department of Medicine , University of Valencia, Hospital Universitario y Politécnico La Fe , Valencia, CIBERONC, Instituto III , Madrid , Spain.
    Itzykson R; d Department of Hematology/Oncology, Saint-Louis Hospital, University of Paris 7 , France.
    Ritchie EK; e Division of Hematology and Oncology, Weill Cornell Medicine and The New York Presbyterian Hospital , New York , NY , USA.
    Sekeres MA; f Leukemia Program Cleveland Clinic , Cleveland , OH , USA.
    Barnard J; f Leukemia Program Cleveland Clinic , Cleveland , OH , USA.
    Podoltsev NA; a Department of Internal Medicine, Section of Hematology, Yale University School of Medicine , New Haven , CT, USA.
    Brunner A; g Massachusetts General Hospital Cancer Center Harvard Medical School , Boston , MA , USA.
    Komrokji RS; h Department of Malignant Hematology , Moffitt Cancer Center and Research Institute , Tampa , FL , USA.
    Bhatt VR; i Division of Hematology/Oncology, University of Nebraska Medical Center , Omaha , NE , USA.
    Al-Kali A; j Mayo Clinic , Rochester , MN , USA.
    Cluzeau T; k Cote d'Azur University, Nice Sophia Antipolis University, CHU of Nice , Nice , France.
    Santini V; l Division of Hematology , University of Florence , Florence , Italy.
    Roboz GJ; e Division of Hematology and Oncology, Weill Cornell Medicine and The New York Presbyterian Hospital , New York , NY , USA.
    Fenaux P; d Department of Hematology/Oncology, Saint-Louis Hospital, University of Paris 7 , France.
    Litzow M; j Mayo Clinic , Rochester , MN , USA.
    Fathi AT; g Massachusetts General Hospital Cancer Center Harvard Medical School , Boston , MA , USA.
    Perreault S; m Department of Pharmacy , Yale New Haven Hospital , New Haven , CT , USA.
    Kim TK; a Department of Internal Medicine, Section of Hematology, Yale University School of Medicine , New Haven , CT, USA.
    Prebet T; a Department of Internal Medicine, Section of Hematology, Yale University School of Medicine , New Haven , CT, USA.
    Vey N; n Department of Hematology , Institut Paoli Calmettes , Marseille , France.
    Verma V; i Division of Hematology/Oncology, University of Nebraska Medical Center , Omaha , NE , USA.
    Germing U; o Department of Hematology , Oncology and Clinical Immunology , Heinrich-Heine-University Duesseldorf , Duesseldorf , Germany.
    Bergua J; p Hospital San Pedro Alcántara , Cáceres , Spain.
    Serrano J; q Division of Hematology/Oncology, University Hospital Reina Sofia , Cordoba , Spain.
    Gore SD; a Department of Internal Medicine, Section of Hematology, Yale University School of Medicine , New Haven , CT, USA.
    Zeidan AM; a Department of Internal Medicine, Section of Hematology, Yale University School of Medicine , New Haven , CT, USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2019 Jan; Vol. 60 (1), pp. 246-249. Date of Electronic Publication: 2018 Jul 02.
    Typ publikacji:
    Letter; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Hematopoietic Stem Cell Transplantation*
    Antineoplastic Combined Chemotherapy Protocols/*pharmacology
    Leukemia, Myeloid, Acute/*therapy
    Neoplasm Recurrence, Local/*therapy
    Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Drug Resistance, Neoplasm ; Female ; Humans ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/pathology ; Male ; Middle Aged ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Retrospective Studies ; Risk Assessment/methods ; Risk Factors ; Survival Analysis ; Transplantation, Homologous ; Treatment Outcome ; Young Adult
    Raport
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes.
    Autorzy:
    Press KR; a Department of Pediatrics , Columbia University Medical Center , NY , USA.
    Uy N; b Deptartment of Internal Medicine, Section of Hematology , Yale University School of Medicine , New Haven , CT , USA.
    Keefer J; c Johns Hopkins University School of Medicine , Baltimore , MD , USA.
    Gore SD; b Deptartment of Internal Medicine, Section of Hematology , Yale University School of Medicine , New Haven , CT , USA.
    Carraway HE; d Taussig Cancer Institute, Hematologic Oncology and Blood Disorders , Cleveland Clinic , Cleveland , OH , USA.
    Sakoian S; c Johns Hopkins University School of Medicine , Baltimore , MD , USA.
    Prebet T; b Deptartment of Internal Medicine, Section of Hematology , Yale University School of Medicine , New Haven , CT , USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2018 Mar; Vol. 59 (3), pp. 755-757. Date of Electronic Publication: 2017 Jul 25.
    Typ publikacji:
    Evaluation Study; Journal Article
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Fetal Hemoglobin/*analysis
    Leukemia, Myeloid, Acute/*blood
    Myelodysplastic Syndromes/*blood
    Aged ; Azacitidine/administration & dosage ; Benzamides/administration & dosage ; Clinical Trials, Phase I as Topic ; Female ; Follow-Up Studies ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/pathology ; Male ; Myelodysplastic Syndromes/drug therapy ; Myelodysplastic Syndromes/pathology ; Prognosis ; Pyridines/administration & dosage
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.
    Autorzy:
    Vey N; a Department of Hematology , Institut Paoli Calmettes, SIRIC-Marseille , Marseille , France.; b Aix-Marseille University , Marseille , France.
    Prebet T; c Internal Medicine Department, Section of Hematology , Yale Cancer Center at Yale University , New Haven , CT , USA.
    Thalamas C; d Department of Medical Pharmacology , CIC 1436, Université Toulouse Hospital, Inserm , Toulouse , France.
    Charbonnier A; a Department of Hematology , Institut Paoli Calmettes, SIRIC-Marseille , Marseille , France.
    Rey J; a Department of Hematology , Institut Paoli Calmettes, SIRIC-Marseille , Marseille , France.
    Kloos I; e Department of Oncology Research and Development , Institut de Recherches Internationales Servier , Suresnes , France.
    Liu E; f Biometrics, Pharmacyclics , LLC, an AbbVie Company , Sunnyvale , CA , USA.
    Luan Y; f Biometrics, Pharmacyclics , LLC, an AbbVie Company , Sunnyvale , CA , USA.
    Vezan R; g Department of Clinical Science, Pharmacyclics , LLC, an AbbVie Company , Sunnyvale , CA , USA.
    Graef T; g Department of Clinical Science, Pharmacyclics , LLC, an AbbVie Company , Sunnyvale , CA , USA.
    Recher C; h Service d'Hématologie , Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole , Toulouse , France.; i Cancer Research Center of Toulouse, UMR1037-INSERM, ERL5294-CNRS , Toulouse , France.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2017 Aug; Vol. 58 (8), pp. 1880-1886. Date of Electronic Publication: 2016 Dec 02.
    Typ publikacji:
    Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Benzofurans/*administration & dosage
    Histone Deacetylase Inhibitors/*administration & dosage
    Hydroxamic Acids/*administration & dosage
    Leukemia, Myeloid, Acute/*drug therapy
    Myelodysplastic Syndromes/*drug therapy
    Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy
    Adult ; Aged ; Benzofurans/adverse effects ; Benzofurans/pharmacokinetics ; Drug Resistance, Neoplasm ; Female ; Histone Deacetylase Inhibitors/adverse effects ; Histone Deacetylase Inhibitors/pharmacokinetics ; Humans ; Hydroxamic Acids/adverse effects ; Hydroxamic Acids/pharmacokinetics ; Leukemia, Myeloid, Acute/diagnosis ; Male ; Middle Aged ; Myelodysplastic Syndromes/diagnosis ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis ; Recurrence ; Retreatment ; Treatment Outcome ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    PcG methylation of the HIST1 cluster defines an epigenetic marker of acute myeloid leukemia.
    Autorzy:
    Tiberi G; CRCM (Epigenetic Factors in Normal and Malignant Hematopoiesis), Inserm, U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105; CNRS, UMR7258, Marseille, France.
    Pekowska A; CIML, CNRS UMR6102, INSERM U631, Aix-Marseille Université, Marseille, France.
    Oudin C; CRCM (Epigenetic Factors in Normal and Malignant Hematopoiesis), Inserm, U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105; CNRS, UMR7258, Marseille, France.
    Ivey A; 1] Department of Medical and Molecular Genetics, King's College London School of Medicine, London, UK [2] GSTS Pathology, Guy's Hospital, London, UK.
    Autret A; CRCM (Epigenetic Factors in Normal and Malignant Hematopoiesis), Inserm, U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105; CNRS, UMR7258, Marseille, France.
    Prebet T; CRCM (Epigenetic Factors in Normal and Malignant Hematopoiesis), Inserm, U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105; CNRS, UMR7258, Marseille, France.
    Koubi M; CRCM (Epigenetic Factors in Normal and Malignant Hematopoiesis), Inserm, U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105; CNRS, UMR7258, Marseille, France.
    Lembo F; CRCM (Epigenetic Factors in Normal and Malignant Hematopoiesis), Inserm, U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105; CNRS, UMR7258, Marseille, France.
    Mozziconacci MJ; CRCM (Epigenetic Factors in Normal and Malignant Hematopoiesis), Inserm, U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105; CNRS, UMR7258, Marseille, France.
    Bidaut G; CRCM (Epigenetic Factors in Normal and Malignant Hematopoiesis), Inserm, U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105; CNRS, UMR7258, Marseille, France.
    Chabannon C; CRCM (Epigenetic Factors in Normal and Malignant Hematopoiesis), Inserm, U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105; CNRS, UMR7258, Marseille, France.
    Grimwade D; Department of Medical and Molecular Genetics, King's College London School of Medicine, London, UK.
    Vey N; CRCM (Epigenetic Factors in Normal and Malignant Hematopoiesis), Inserm, U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105; CNRS, UMR7258, Marseille, France.
    Spicuglia S; CIML, CNRS UMR6102, INSERM U631, Aix-Marseille Université, Marseille, France.
    Calmels B; CRCM (Epigenetic Factors in Normal and Malignant Hematopoiesis), Inserm, U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105; CNRS, UMR7258, Marseille, France.
    Duprez E; CRCM (Epigenetic Factors in Normal and Malignant Hematopoiesis), Inserm, U1068; Institut Paoli-Calmettes; Aix-Marseille Université, UM105; CNRS, UMR7258, Marseille, France.
    Pokaż więcej
    Źródło:
    Leukemia [Leukemia] 2015 May; Vol. 29 (5), pp. 1202-6. Date of Electronic Publication: 2014 Dec 08.
    Typ publikacji:
    Letter; Research Support, Non-U.S. Gov't
    MeSH Terms:
    DNA Methylation*
    Epigenesis, Genetic*
    Multigene Family*
    Histones/*genetics
    Leukemia, Myeloid, Acute/*genetics
    Aged ; Biomarkers/metabolism ; Chromatin/metabolism ; Female ; Gene Expression Profiling ; Gene Expression Regulation ; Gene Expression Regulation, Leukemic ; Humans ; Male ; Middle Aged ; Mutation ; Nuclear Proteins/genetics ; Nucleophosmin
    Raport
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse.
    Autorzy:
    Park S; Service d'Hématologie, INSERM U1016, Institut Cochin, Hôpital Cochin, AP-HP, Paris, France. />Chapuis N
    Saint Marcoux F
    Recher C
    Prebet T
    Chevallier P
    Cahn JY
    Leguay T
    Bories P
    Witz F
    Lamy T
    Mayeux P
    Lacombe C
    Demur C
    Tamburini J
    Merlat A
    Delepine R
    Vey N
    Dreyfus F
    Béné MC
    Ifrah N
    Bouscary D
    Pokaż więcej
    Corporate Authors:
    GOELAMS (Groupe Ouest Est d’Etude des Leucémies aiguës et Autres Maladies du Sang)
    Źródło:
    Leukemia [Leukemia] 2013 Jul; Vol. 27 (7), pp. 1479-86. Date of Electronic Publication: 2013 Jan 16.
    Typ publikacji:
    Clinical Trial, Phase I; Journal Article; Multicenter Study
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
    Cytarabine/*administration & dosage
    Daunorubicin/*administration & dosage
    Leukemia, Myeloid, Acute/*drug therapy
    Sirolimus/*analogs & derivatives
    TOR Serine-Threonine Kinases/*antagonists & inhibitors
    Adult ; Aged ; Antibiotics, Antineoplastic/administration & dosage ; Antibiotics, Antineoplastic/adverse effects ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cytarabine/adverse effects ; Daunorubicin/adverse effects ; Everolimus ; Female ; Humans ; Male ; Middle Aged ; Recurrence ; Signal Transduction/drug effects ; Sirolimus/administration & dosage ; Sirolimus/adverse effects ; Treatment Outcome ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
    Autorzy:
    Prebet T
    Charbonnier A
    Gelsi-Boyer V
    Mozziconacci MJ
    Blaise D
    Vey N
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2013 Jul; Vol. 54 (7), pp. 1538-40. Date of Electronic Publication: 2012 Nov 29.
    Typ publikacji:
    Letter
    MeSH Terms:
    Leukemia, Myeloid, Acute/*drug therapy
    Leukemia, Myeloid, Acute/*pathology
    Myelodysplastic Syndromes/*drug therapy
    Thalidomide/*analogs & derivatives
    Azacitidine/administration & dosage ; Azacitidine/therapeutic use ; Humans ; Lenalidomide ; Leukemia, Myeloid, Acute/mortality ; Myelodysplastic Syndromes/mortality ; Thalidomide/administration & dosage ; Thalidomide/therapeutic use ; Treatment Failure ; Treatment Outcome
    Opinia redakcyjna
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia.
    Autorzy:
    Devillier R; Hematology Department, Institut Paoli-Calmettes, Marseille, France.
    Crocchiolo R
    Etienne A
    Prebet T
    Charbonnier A
    Fürst S
    El-Cheikh J
    D'Incan E
    Rey J
    Faucher C
    Blaise D
    Vey N
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2013 Jun; Vol. 54 (6), pp. 1228-34. Date of Electronic Publication: 2012 Nov 19.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Hematopoietic Stem Cell Transplantation*
    Leukemia, Myeloid, Acute/*therapy
    Adolescent ; Adult ; Aged ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/mortality ; Middle Aged ; Prognosis ; Recurrence ; Salvage Therapy ; Transplantation, Homologous ; Treatment Outcome ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT.
    Autorzy:
    Devillier R; Department of Hematology, Transplantation Program, Gene and Cell Therapy program, Institut Paoli Calmettes, Marseille, France.
    Crocchiolo R
    Castagna L
    Fürst S
    El Cheikh J
    Faucher C
    Prebet T
    Etienne A
    Chabannon C
    Vey N
    Esterni B
    Blaise D
    Pokaż więcej
    Źródło:
    Bone marrow transplantation [Bone Marrow Transplant] 2012 May; Vol. 47 (5), pp. 639-45. Date of Electronic Publication: 2012 Feb 06.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antilymphocyte Serum/*therapeutic use
    Graft vs Host Disease/*prevention & control
    Leukemia, Myeloid, Acute/*therapy
    Myelodysplastic Syndromes/*therapy
    Transplantation Conditioning/*methods
    Adolescent ; Adult ; Aged ; Animals ; Busulfan/therapeutic use ; Graft vs Host Disease/drug therapy ; Graft vs Host Disease/etiology ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Leukemia, Myeloid, Acute/complications ; Leukemia, Myeloid, Acute/drug therapy ; Middle Aged ; Myelodysplastic Syndromes/complications ; Myelodysplastic Syndromes/drug therapy ; Rabbits ; Recurrence ; Retrospective Studies ; Survival Analysis ; Transplantation Conditioning/adverse effects ; Vidarabine/analogs & derivatives ; Vidarabine/therapeutic use
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1.
    Autorzy:
    Chaib H; Inserm, U891, Centre de Recherche en Cancérologie de Marseille, Marseille, France.
    Nebbioso A
    Prebet T
    Castellano R
    Garbit S
    Restouin A
    Vey N
    Altucci L
    Collette Y
    Pokaż więcej
    Źródło:
    Leukemia [Leukemia] 2012 Apr; Vol. 26 (4), pp. 662-74. Date of Electronic Publication: 2011 Oct 07.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Agents/*pharmacology
    Apoptosis/*drug effects
    Leukemia, Myeloid, Acute/*drug therapy
    Methyltransferases/*antagonists & inhibitors
    Receptors, Death Domain/*physiology
    Repressor Proteins/*antagonists & inhibitors
    Animals ; Caspases/physiology ; Humans ; Leukemia, Myeloid, Acute/pathology ; Mice ; Piperazines/pharmacology ; Reactive Oxygen Species/metabolism ; U937 Cells ; Xenograft Model Antitumor Assays
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study.
    Autorzy:
    Chevallier P; Service d'Hématologie Clinique, CHU and Université de Nantes, INSERM U892, Nantes, France.
    Labopin M
    Turlure P
    Prebet T
    Pigneux A
    Hunault M
    Filanovsky K
    Cornillet-Lefebvre P
    Luquet I
    Lode L
    Richebourg S
    Blanchet O
    Gachard N
    Vey N
    Ifrah N
    Milpied N
    Harousseau JL
    Bene MC
    Mohty M
    Delaunay J
    Pokaż więcej
    Źródło:
    Leukemia [Leukemia] 2011 Jun; Vol. 25 (6), pp. 939-44. Date of Electronic Publication: 2011 Feb 18.
    Typ publikacji:
    Journal Article; Validation Study
    MeSH Terms:
    Prognosis*
    Severity of Illness Index*
    Leukemia, Myeloid, Acute/*pathology
    Adult ; Aged ; Aminoglycosides/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Disease-Free Survival ; Gemtuzumab ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Middle Aged ; Recurrence ; Salvage Therapy/methods ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-15 z 15

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies